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Abstract
Malaria-associated acute lung injury (MA-ALI) and its more severe form malaria-associated
acute respiratory distress syndrome (MA-ARDS) are common, often fatal complications of
severe malaria infections. However, little is known about their pathogenesis. In this study,
biochemical alterations of the lipid composition of the lungs were investigated as possible
contributing factors to the severity of murine MA-ALI/ARDS. C57BL/6J mice were infected
with Plasmodium berghei NK65 to induce lethal MA-ARDS, or with Plasmodium chabaudi
AS, a parasite strain that does not induce lung pathology. The lipid profile of the lung tissue
from mice infected with Plasmodium berghei NK65 developing MA-ALI/ARDS, but not that
from mice without lung pathology or controls, was characterized by high levels of phospho-
lipids -mainly phosphatidylcholine- and esterified cholesterol. The high levels of polyunsatu-
rated fatty acids and the linoleic/oleic fatty acid ratio of the latter reflect the fatty acid
composition of plasma cholesterol esters. In spite of the increased total polyunsaturated
fatty acid pool, which augments the relative oxidability of the lung membranes, and the pres-
ence of hemozoin, a known pro-oxidant, no excess oxidative stress was detected in the
lungs of Plasmodium berghei NK65 infected mice. The bronchoalveolar lavage (BAL) fluid
of Plasmodium berghei NK65 infected mice was characterized by high levels of plasma pro-
teins. The phospholipid profile of BAL large and small aggregate fractions was also different
from uninfected controls, with a significant increase in the amounts of sphingomyelin and
lysophosphatidylcholine and the decrease in phosphatidylglycerol. Both the increase of pro-
teins and lysophosphatidylcholine are known to decrease the intrinsic surface activity of sur-
factant. Together, these data indicate that an altered lipid composition of lung tissue and
BAL fluid, partially ascribed to oedema and lipoprotein infiltration, is a characteristic feature
of murine MA-ALI/ARDS and possibly contribute to lung dysfunction.
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Introduction
According to the WHO classification, deep breathing, respiratory distress and pulmonary
oedema are among the clinical features occurring in severe malaria accompanied by lung com-
plications [1–3]. Malaria-associated acute lung injury (MA-ALI), and its more severe form,
malaria-associated acute respiratory distress syndrome (MA-ARDS) are prevalent in malaria-
endemic areas with low transmission where adults get severe complications because protective
clinical immunity is lacking [4, 5]. The precise incidence is not known, but it has been esti-
mated between<2% to>25% in severe malaria cases, and mortality may be as high as 80%
when mechanical ventilation is not available [5]. Up to 60% of severe zoonotic malaria cases
caused by P. knowlesi develop MA-ARDS [6]. Knowledge about the pathogenesis of MA-ALI/
ARDS is still limited, and especially the biochemical alterations associated with lung dysfunc-
tion have not been investigated, yet. Therefore, murine models have been developed, which are
useful to perform detailed experiments to unravel the pathogenesis of MA-ALI/MA-ARDS [7,
8]. Although the histopathology and also the ultrastructure of murine MA-ARDS is similar to
post-mortem analyses of human MA-ARDS cases, [9] the findings from mouse models must
be confirmed in patient studies, since important differences may exist between human malaria
and corresponding mouse models [10]. Inflammation and increased endothelial permeability
are important features of both human and mouse MA-ALI/ARDS [3, 5, 8, 11–14]. High num-
bers of inflammatory cells are observed in lung biopsies from patients and mice that suc-
cumbed from this complication [5] and a significantly altered expression profile of
inflammatory mediators was found in the lungs of mice with MA-ARDS [7]. Accumulation of
hemozoin (Hz), the major waste product of hemoglobin degradation, in the lungs appears to
be an important inflammatory stimulus contributing to MA-ARDS. Pulmonary Hz levels are
significantly correlated with inflammation, increased lung weight and alveolar oedema in mice
[15], and increasing amounts of Hz are observed on lung autopsies from African children with
increasing disease severity [13]. Activated inflammatory cells and Hz can also cause oxidative
stress, which may augment inflammation and contribute to vascular leakage and alveolar
oedema [14–15]. Oxidative degradation of lipids results in the accumulation of reactive alde-
hydes, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), which are highly
cytotoxic [16, 17]. An altered lipid profile and increased levels of lipoperoxidation end products
have been found in plasma from patients with ARDS of different aetiologies, however, no data
are available on MA-ARDS [18, 19].
ARDS is also often associated with lung surfactant disorders, which can be observed soon
after the initial injurious event and lead to increased surface tension, alveolar collapse and loss
of liquid balance in the lungs [20, 21]. Pulmonary surfactant is synthesized by alveolar type II
cells and consists of a lipoprotein complex with an essential role in reducing the surface tension
at the air-liquid interface of lung epithelia and in lung immune defence. The lipid part is mainly
composed of phospholipids (PLs), predominantly dipalmitoylphosphatidylcholine (DPPC)
[22, 23] and high levels of phosphatidylglycerol (PG) whereas approximately 10% of the surfac-
tant consists of specific proteins which contribute to the first-line defence against pulmonary
pathogens to prevent infection and inflammation and aid in the adsorption of lipids. The
newly synthesized surfactant is stored as tightly packed membranes known as lamellar bodies
which are secreted into the alveolar hypophase as large multilamellar vesicles, known as the
large aggregate (LA) surfactant fraction [23, 24]. The LA fraction acts as a reservoir for the sur-
factant layers that are spread as a surface film over the alveolar liquid-air interface. During
breathing, LA is converted into small vesicles that are degraded by macrophages or recycled by
the type II pneumocytes. These small vesicles are less surface active and constitute the small
aggregate (SA) surfactant fraction [23].
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Inflammation enhances the conversion of LA into SA [25, 26] and results in phospholipase
A2 (PLA2) enzymatic degradation of mainly DPPC, the most abundant surfactant phospho-
lipid, thereby generating equimolar amounts of lysophosphatidylcholine (LPC) and free pal-
mitic acid [27, 28]. LPC, together with plasma proteins and specific free fatty acids that leak
into the alveoli when vascular permeability is increased and the epithelial membrane is dam-
aged, can interfere with normal surfactant activity and compromise lung compliance.
To deepen our understanding on the complexity of the pathological changes occurring dur-
ing MA-ALI/ARDS, we explored the biochemical modifications and lipid alterations of lung
tissue and the molecular organization and lipid composition of alveolar surfactant in C57BL/6J
mice infected with Plasmodium berghei NK65 (PbNK65), a well-established murine model of
MA-ARDS. As a control, mice infected with Plasmodium chabaudi AS (PcAS), a Plasmodium
strain that does not induce lung pathology, were used [7].
Materials and Methods
Reagents
Unless differently specified all chemicals were purchased from Sigma (Milan, Italy). Standard
fatty acid methylesters were purchased from Alltech (Milan, Italy) and silica gel plates (Kiesel-
gel 60) for High Performance Thin layer Chromatography (HPTLC) fromMerck (Darmstadt,
Germany).
Animals
Infection of mice with rodent malaria parasites. C57BL/6J mice (8–9 weeks of age,
approximately 50% males and 50% females, all groups were age and sex-matched in all experi-
ments) were infected by intraperitoneal injection of 104 PbNK65 or PcAS infected red blood
cells (RBCs). Peripheral parasitemia was determined by 10% Giemsa staining of blood smears
followed by microscopic counting and expressed as percentage of infected red blood cells. Mice
were sacrificed at day 8 or 10 post infection and blood was removed by heart puncture. All
experiments were approved by the Animal Ethics Committee from the KU Leuven (License
LA1210186, Belgium). All efforts were made to minimize suffering. Mice were euthanized by
intraperitoneal injection of a lethal dose of sodium pentobarbital (200 μl at 60 mg/ml
Nembutal).
Treatment of infected mice with dexamethasone (DEX). Mice were treated with dexa-
methasone before the onset of MA-ARDS, according to previously published findings [7].
Briefly, dexamethasone sodium phosphate (DEX; CERTA, Braine-l’Alleud, Belgium) was dis-
solved in phosphate-buffered saline (PBS) and injected intraperitoneally at 80 mg/kg, in a vol-
ume of 200 μl daily, starting at day 6–7 post infection. As a control, another group of PbNK65
infected mice was treated with PBS alone.
Preparation of biological specimens
At the indicated time points, mice were sacrified. Blood was drawn by cardiac puncture into
heparin-coated syringes and centrifuged to separate plasma and RBCs. Subsequently, left lungs
were pinched off with a clamb. The bronchoalveolar lavage (BAL) and the perfusion with 0.15
M NaCl containing 0.2 mM butylhydroxytoluene (BHT) as an antioxidant, were performed
only on the right lungs. The left lungs were weighted with a laboratory balance, whereas the
right lungs were removed and homogenized in Precellys tubes in 6 volumes of a solution con-
taining 20 mM Tricine, 250 mM sucrose, 5 mM EDTA, 0.2 mM BHT (pH 7.4) and a protease
inhibitor cocktail (Sigma). Lung homogenates were further centrifuged at 1,000xg for 10 min
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(4°C), washed three times in the same buffer and the pooled supernatants were centrifuged at
100,000xg for 1 hour (4°C). The pellets, representing the enriched membrane fraction, were
resuspended in 0.2 mM BHT and stored at -80°C until further analyses.
BAL fluid was collected from the right lungs by intra-tracheal instillation of an isotonic
NaCl solution (3 x 0.6 ml) through a trachea cannula and centrifuged at 150xg for 10 min at
4°C to pellet the cells. The total (cell-free) supernatant was collected and immediately centri-
fuged at 12,000xg for 30 min (4°C) to obtain a Large Aggregate fraction (LA, pellet) and a
Small Aggregate fraction (SA, supernatant) as described previously [29]. LA and SA fractions
were lyophilized, resuspended in distilled water and stored at -80°C until further processing.
Hemozoin determination
Perfused lungs were used for the determination of the Hz content by heme-enhanced chemolu-
minescence according to Deroost et al [30]. The Hz concentration (nM) in the homogenates
was calculated from the calibration curve of the hematin concentration (nM) versus lumines-
cence (events/sec) and subsequently expressed as pmol Hz/mg tissue.
Lipid analyses
Lipids in plasma, BAL fluid and lung samples were extracted in organic solvents according to
Folch [31]. The lipid extracts were dried under nitrogen, dissolved in chloroform and saved at
-80°C until further analyses. Phospholipid (PL) phosphorus was determined by the Bartlett
procedure [32] and PLs were separated by HPTLC plates with chloroform/methanol/acetic
acid/water = 60:40:4:2 (v/v/v/v) as developing solvent. Spots were visualized with anisaldehyde
[33] and quantified by densitometric analysis (Camag Reprostar 3). Cholesterol (Cho), triglyc-
erides (TG) and cholesterol esters (ChoE) were quantified by densitometric analysis after sepa-
ration by HPTLC in hexane/diethyl ether/acetic acid (90:10:1 by vol.) and visualized with a
solution of 10% CuSO4 in 8% H3PO4. The fatty acid composition of the lipid fractions were
analyzed by gas liquid chromatography (GLC) according to Corsetto et al. [34]. Lipid peroxida-
tion was measured in the sample homogenates by determining the levels of thiobarbituric acid
reactive substances (TBARS) as previously reported [35] and expressed as pmoles of malon-
dialdehyde (MDA)/mg protein.
The collagen content of lungs, a marker of fibrotic degeneration, was determined by mea-
suring hydroxyproline in the tissue homogenates [36].
Statistical analysis
Results are reported as mean ± standard deviation (SD). Comparison between groups and rep-
licates was performed using ANOVA followed by Tukey's multiple comparison test with
GraphPad Prism 6.0 (Graphpad Software Inc., La Jolla, CA, USA). The differences were con-
sidered significant when p< 0.05.
Results
Disease course in mice infected with PbNK65 or PcAS
C57BL/6J mice were infected intraperitoneally with 104 RBC from mice infected with PbNK65
or PcAS and the development of parasitemia was monitored over time. The parasitemia
increased steadily in PbNK65-infected mice from day 0 to day 10, whereas a significantly lower
parasitemia was detected in PcAS-infected mice (Fig 1A). Corresponding to previous observa-
tions [7], extensive and lethal pulmonary pathology developed from day 8 post infection
onwards in PbNK65-infected mice as indicated by the increased weight and the swollen
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appearance of the lungs that was absent in PcAS-infected mice (Fig 1B and 1C). PbNK65 infec-
tion also resulted in a higher deposition of Hz in the lungs compared to PcAS infected mice
(Fig 1D). This contributes, in addition to haemorrhages, to the dark brown aspect of the lungs
from PbNK65-infected mice (Fig 1C) and is consistent with earlier observations [7].
Alterations in the lipid profile of lung membranes from mice with
MA-ARDS
To investigate whether malaria infection alters the lipid composition of the lung tissue, we
infected mice with PbNK65, which causes MA-ARDS, or PcAS, which does not cause
MA-ARDS. Furthermore, to investigate whether the lipid and FA changes observed in the lungs
are specific for MA-ARDS or merely due to the parasite infection, one group of PbNK65-in-
fected mice was treated daily with 80 mg/kg DEX starting on day 7 after infection before the
appearance of the pulmonary symptoms. This treatment regimen has been shown previously to
prevent the development of pulmonary pathology without decreasing parasitemia [7].
The lipids of membrane-rich fractions from lung homogenates were analyzed. No differ-
ences were found between infected and non-infected control (CTR) mice in the level of free
cholesterol (μg Cho/mg protein: CTR 143.5 ± 46¸ PcAS day 10: 124.2 ± 61; PbNK65 day 10:
132.6 ± 40). Significantly higher levels of PLs and esterified Cho (ChoE) were found in lungs
obtained from PbNK65-infected mice compared to CTR or PcAS-infected mice at day 8 and 10
Fig 1. Disease course in mice infected with PbNK65 or PcAS. C57BL/6J mice were injected intraperitoneally with 104 erythrocytes infected with
Plasmodium berghei (PbNK65) or P. chabaudi AS (PcAS). Peripheral parasitemia (panel A) and weights of the left lungs (panel B) were determined at day 6,
8 and 10 post infection (n = 6–8 mice for each time point and strain). (panel C) Representative pictures of right lungs (not perfused) from uninfected (CTR) or
infected mice (day 10 post infection). (panel D) Hz content in lung tissue (pmole Hz /mg lung tissue) at day 10 post infection. *p<0.05; **p<0.01; ***
p<0.0001 vs CTR; °°°p< 0.01 PbNK65 vs PcAS.(n = 6–8 mice for each time point and strain).
doi:10.1371/journal.pone.0143195.g001
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post infection (Fig 2A and 2B). Phosphatidylcholine (PC), the most abundant PL found in the
lungs, increased in parallel with the increased disease severity (Fig 2C). The treatment with
DEX prevented the rise in PLs, ChoE and PC in the lung tissue (Fig 2A, 2B and 2C) at day 10
post infection. No differences were found for phosphatidylethanolamine (PE), sphingomyelin
(SM) and phosphatidylinositol (PI) between infected and non-infected CTR mice (not shown).
From the analysis of the fatty acid (FA) profile, the total lung membrane-enriched fraction
from PbNK65-infected mice was characterized by higher percentages of palmitic acid (C16:0)
and lower percentages of stearic (C18:0) and oleic (C18:1) acid compared to PcAS and CTR
mice at both day 8 and 10 post infection (Table 1). The levels of linoleic (C18:2 n-6) acid were
also slightly reduced The percentage of docosahexaenoic acid (DHA, C22:6 n-3) was increased
by the infection, with no differences between the two parasite strains. The percentages of the
other FAs in the total membrane fraction were not affected in the infected animals compared
to controls. Due to the high content of DHA, the Peroxidability Index (PI) of the lung tissue
from infected mice of both strains was significantly higher compared to CTR mice, indicating a
higher relative oxidability of the membranes. The treatment of PbNK65-infected mice with
DEX did not significantly affect the fatty acid distribution of lung tissue and consequently the
relative oxidability index (PI). In particular, no effect of DEX was found on the levels of DHA
(Table 1).
By examining the FA profile of PC and ChoE, the two molecular species significantly
increased in MA-ARDS, it was found that PC was extremely rich in palmitic acid (48%) and
similar in CTR and infected mice, whereas the ChoE fraction in lung membranes of
PbNK65-infected mice was characterized by higher percentages of DHA (6.9% vs 3.8% of
CTR), linoleic (25.4% vs 16.2% of CTR), and arachidonic acid (26.4% vs 13.7% of CTR) and a
higher linoleic/oleic acid ratio (2.3 vs 1.0 of CTR).
Oxidative damage and fibrosis
In spite of the higher amounts of total membrane PLs present in the lungs of mice with
MA-ARDS, and the higher total amounts of polyunsaturated fatty acids (PUFAs), the levels of
lipoperoxidation products (TBARS) did not indicate higher oxidative damage in the lungs of
infected PbNK65 mice compared to controls or to PcAS-infected mice. In agreement, any
fibrotic degeneration was excluded since the levels of hydroxyproline, a marker of collagen
deposition, were within the normal range (S1 Fig).
Lipid changes in plasma
Since vascular leakage is a feature of MA-ARDS, and plasma contains a large amount of lipids
transported by lipoproteins, it was investigated whether the lipid and FA alterations found in
the lungs of PbNK65-infected mice might be related to plasma leakage and lipoprotein infiltra-
tion. Compared to CTR or PcAS-infected mice, the lipid profile in plasma of PbNK65-infected
mice was significantly modified only at day 10 post infection showing an increase of TG, free
Cho and the Cho/ChoE ratio (Fig 3), an increase of PC, PE and SM and a decrease of LPC (Fig
4). Analogously to the lungs, the total fatty acid profile of plasma from PbNK65-infected mice
(day 10 post infection) showed lower levels of linoleic acid (C18:2) and higher levels of arachi-
donic (C20:4) and DHA (C22:6), but similar levels of the saturated palmitic (C16:0) and stearic
(C18:0) fatty acids (Table 2). Interestingly, significantly lower percentages of linoleic
(27.05 ± 1.1 PbNK65 vs 40.13 ± 2.5 CTR) and higher percentages of arachidonic acid
(42.46 ± 0.4 PbNK65 vs 29.34 ± 3.4 CTR) and DHA (8.56 ± 1.6 PbNK65 vs 5.09 ± 0.4 CTR)
were also found in the purified plasma (ChoE) fraction.
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Fig 2. Alteration in the lipid profiles of the lungs from uninfected, PbNK65 or PcAS infectedmice.Mice
infected with PbNK65 (treated or not intraperitoneally with DEX 80mg/kg) or PcAS were perfused and
dissected at day 8 and 10 post infection. The total content of PL (panel A), ChoE (panel B), PC (panel C) /mg
protein were determined as described in Materials and Methods. n = 6 mice for each condition; *p<0.05;
**p<0.01; ***p<0.0001 vs CTR; °p< 0.05; °°p<0.01; °°°p<0.0001 vs PcAS for each time point; $ p<0.05
PbNK65-DEX vs PbNK65 day 10. PL = phospholipids; ChoE = Cholesterol Esters;
PC = phosphatidylcholine.
doi:10.1371/journal.pone.0143195.g002
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Alteration of the alveolar surfactant composition in murine MA-ARDS
The total (cell-free) BAL fluid of PcAS-infected mice showed a limited, although significant,
increase in protein levels at 8 and 10 days post infection (Table 3). The increase in protein con-
tent was more pronounced in mice infected with PbNK65 at each time point analyzed. PLs
were also significantly increased in BAL in both PcAS and PbNK65-infected mice, with the
highest levels detected at day 10 in PbNK65-infected mice (Table 3). The amount of the LA
fraction obtained from PbNK65- or PcAS-infected mice was not significantly different from
that of non-infected CTR mice (S2 Fig). However, the composition of the LA fraction was sig-
nificantly altered in PbNK65-infected mice at day 10 post infection, being characterized by an
increased protein content (Fig 5) and a modified PL composition (Fig 6A). A significant
increase in the relative amounts of SM and a decrease in phosphatidylglycerol (PG) were
observed, whereas the percentages of PC and PE were not altered (Fig 6A and data not shown).
The PL composition of the SA fraction was altered as well, with almost undetectable PG and a
dramatic increase in LPC, the hydrolysis product of PC (Fig 6B).
Discussion
This study illustrates that the lipid and FA profile of lung tissue is significantly altered during
murine MA-ARDS. Increased levels of PLs and ChoE were found in the membrane-enriched
fraction of PbNK65-infected mice, which develop significant lung pathology, compared to
Table 1. Fatty acid distribution in the membrane rich fraction of lung tissue from control, PcAS and PbNK65 (treated or not with dexamethasone)
infectedmice at different times after the infection.
Fatty acids % of total
CTR PcAS day 8 PcAS day 10 PbNK65 day 8 PbNK65 day 10 PbNK-DEX day 10
C16:0 (palmitic acid) 28.7 ± 3.0 32.25 ± 8.1 30.2 ± 5.1 35.6 ± 4.0 * 36.7 ± 6.1 * 32.99 ± 8.8
C16:1 (palmitoleic acid) 2.98 ± 0.1 1.42 ± 1.0 1.21 ± 0.9 3.29 ± 1.2 2.28 ± 1.4 2.95 ± 1.3
C18:0 (stearic acid) 11.65 ± 2.0 14.01 ± 1.4 13.01 ± 0.4 9.9 ± 1.6 **,°° 8.9 ± 1.1 **,°° 11.20 ± 1.2 °,$
C18:1 (oleic acid) 15.16 ± 1.2 12.90 ± 0.4 11.98 ± 0.4 9.98 ± 1.1 ***,° 9.5 ± 0.9 ***, ° 11.22 ± 1.1 *,$$
C18:2 n-6 (linoleic acid) 11.71 ± 1.1 11.73 ± 1.0 11.65 ± 1.0 10.5 ± 1.4 *,° 10.01 ± 1.1 *, ° 11.66 ± 1.2
C18:3 α (α-linolenic acid) 1.08 ± 0.9 1.02 ± 0.1 1.0 ± 0.1 1.05 ± 1.6 1.0 ± 0.9 1.25 ± 0.1
C18:3 γ (γ-linolenic acid) 2.01 ± 1.1 1.98 ± 0.1 2.04 ± 0.1 1.45 ± 1.2 1.38 ± 1.7 1.98 ± 0.1
C20:3 n-6 (eicosatrienoic acid) 1.47 ± 0.4 1.74 ± 0.5 1.24 ± 0.5 1.35 ± 0.2 1.75 ± 0.2 1.60 ± 0.3
C20:4 n-6 (arachidonic acid) 11.67 ± 1.9 12.65 ± 2.5 11.98 ± 2.0 12.01 ± 1.9 12.3 ± 1.01 13.97 ± 2.8
C20:5 n-3 (eicosapentaenoic acid) 0.40 ± 0.1 0.39 ± 0.2 0.6 ± 0.2 0.42 ± 0.1 0.39 ± 0.1 0.38 ± 0.2
C22:5 n-3 (docosapentaenoic acid) 2.12 ± 0.2 2.16 ± 0.6 1.99 ± 0.8 1.2 ± 0.2 1.9 ± 0.2 2.06 ± 0.8
C22:6 n-3 (docosahexanoic acid) 4.07 ± 0.9 6.98 ± 0.4 ** 7.1 ± 0.1 ** 7.2 ± 0.9 ** 8.4 ± 0.8 *** 7.72 ± 0.9 **
PI1 (Peroxidability index) 111.62 139.35 * 136.62 * 130.99 * 145.94 ** 148.51**
*p<0.05;
**p<0.01;
***p<0.001 vs CTR;
°p<0.05;
°°p<0.01 PbNK65 vs PcAS;
$ p<0.05;
$$p<0.01 PbNK65-DEX vs PbNK65 for each time point.
n = 5–6
1 PI: of lipids. The value is calculated based on the relative oxidation rate of unsatured fatty acids as follows:
PI = (%monoenoic x 0.025)+(%dienoic x 1)+(%trienoic x 3)+(%tetraenoic x 4)+ (%pentaenoic x 6)+(hexaenoic x 8)
doi:10.1371/journal.pone.0143195.t001
Lipid Changes in Malaria-Associated Lung Pathology
PLOS ONE | DOI:10.1371/journal.pone.0143195 December 1, 2015 8 / 16
PcAS-infected mice or uninfected controls. PbNK65-infected mice also manifest higher parasi-
taemia and higher hemozoin deposition than PcAS-infected mice. The increase in lung PL is a
common, although not universal response to pulmonary inflammation and may be partially
explained by an increase of intra or extracellular surfactant [37, 38]. In fact, PC, the main PL of
surfactant, was also increased in the lung tissue of PbNK65-infected mice and was particularly
rich in palmitic acid, the most abundant fatty acid of surfactant [39]. However, the increased
levels of palmitic acid may be also partially contributed by an impairment of the elongation
pathway to stearic (C18:0) and desaturation to oleic acid (C18:1).
The increase of ChoE suggests a correlation with interstitial oedema and lipoprotein infiltra-
tion occurring during MA-ARDS. Indeed, plasma is rich in ChoE-containing lipoproteins,
which may leak out of the vessels upon increased permeability. This is confirmed by the obser-
vation that in PcAS mice, which show no signs of oedema, the levels of ChoE are low. The pres-
ence of oedema, inflammatory cells and infected erythrocytes is an hallmark of both human
and experimental MA-ARDS caused by different Plasmodium species [9]. The lipoprotein
infiltration is suggested also by the fatty acid composition of ChoE from PbNK65-infected
lungs, which reflects the peculiar fatty acid composition of plasma ChoE: high linoleic, arachi-
donic and DHA fatty acids and high linoleic/oleic fatty acids ratio. The high linoleic/oleic ratio
of plasma ChoE indicates that the majority of the ChoE is derived from the activity of the
plasma Lecithin Cholesterol AcylCoA Transferase (LCAT), shown to be highly specific for
Fig 3. Alteration in the lipid profile of plasma from uninfected, PbNK65 or PcAS infectedmice. PL
(panel A) and neutral lipid content (panel B) of plasma of infected and uninfected mice at day 10 post infection
were determinated as described in Materials and Methods.Cho = Cholesterol, ChoE = Cholesterol esters,
TG = Triacylglycerols. *p<0.05; **p<0.01 vs CTR; °p<0.01 PbNK65 vs PcAS. n = 8–12.
doi:10.1371/journal.pone.0143195.g003
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Fig 4. Alteration of the PL composition in plasma from uninfected, PbNK65 or PcAS infectedmice.
The distribution of plasma PL (mg/100 ml) was determined in uninfected and in PbNK65 or PcAS infected
mice at day 10 post infection. LPC = lysophosphatidylcholine; SM = sphingomyelin;
PC = phosphatidylcholine; PI = phosphatidylinositol; PE = phosphatidylethanolamine. * p<0.05; ** p<0.01 vs
CTR; *** p<0.001 vs CTR. n = 8–12.
doi:10.1371/journal.pone.0143195.g004
Table 2. Plasma fatty acid distribution (%) at day 10 post infection.
Fatty acids % of total
CTR PcAS day 10 PbNK65 day 10
C16:0 (palmitic acid) 19.06 ± 2.8 21.71 ± 1.8 18.11 ± 2.2
C16:1 (palmitoleic acid) 1.90 ± 1.0 1.27 ± 0.4 0.72 ± 1.1 *
C18:0 (stearic acid) 11.75 ± 3.5 10.54 ± 2.3 11.48 ± 2.0
C18:1 (oleic acid) 13.63 ± 1.9 12.98 ± 1.7 13.10 ± 3.7
C18:2 n-6 (linoleic acid) 33.02 ± 4.8 30.43 ± 3.7 26.90 ± 0.2 *
C18:3 α (α-linolenic acid) 0,98 ± 0,4 0,95 ± 0,2 0,47 ± 0.2 *
C18:3 γ (γ-linolenic acid) 1.14 ± 0.1 1.17 ± 2.5 0.66 ± 0.3 *
C20:3 n-6 (eicosatrienoic acid) 13.42 ± 2.8 14.13 ± 2.5 16.25 ± 1.9 *
C20:4 n-6 (arachidonic acid) 0.49 ± 0.1 0.36 ± 0.1 0.43 ± 0.1
C20:5 n-3 (eicosapentaenoic acid) 0.39 ± 0.02 0.57± 0.1 * 0.59 ± 0.1 **
C22:5 n-3 (docosapentaenoic acid) 4.21 ± 1.3 6.48 ± 0.2 * 10.87 ± 1.0 ***
C22:6 n-3 (docosahexanoic acid) 130.29 ± 28.5 177 ± 21.6 187.78 ± 14.2 *
PI1 (Peroxidability index) 2.70 ± 0.9 2.18 ± 0.5 1.68 ± 0.4 *
1 PI: Peroxidability index of lipids. The value is calculated based on the relative oxidation rate of unsatured fatty acids as follows:
PI = (%monoenoic x 0.025)+(%dienoic x 1)+(%trienoic x 3)+(%tetraenoic x 4)+ +(%pentaenoic x 6)+(hexaenoic x 8)
*p<0.05;
**p<0.01;
*** p<0.0001 vs CTR
n = 5
doi:10.1371/journal.pone.0143195.t002
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linoleic acid, rather than from the hepatic AcylCoA Cholesterol Acyl Transferase (ACAT)
activity, more specific for oleic acid [40]. Differently from the increase of PLs and ChoE, the
increase of DHA seems to be related to the malaria infection and not to the lung pathology
since it is present also in PcAS-infected mice and is not inhibited by DEX treatment. Moreover,
we tend to exclude that the modification of plasma lipid content and composition are related
to the lysis of infected erythrocytes. In fact, preliminary data indicate that there are no differ-
ences in the PL composition of RBC plasma membranes from PbNK65- infected mice com-
pared to control or PcAS- infected mice. Furthermore, the high levels of TG present in the
plasma cannot be attributed to RBS lysis since TG are found in trace amounts in RBC mem-
branes. High levels of TG as well as PE may derive from an impairment of lipoprotein lipase
(LPL) activity of PbNK65-infected mice, as reported in other models of hyperlipidemia related
to infection and inflammation [41, 42]. Based on these observations, the changes in plasma
lipid composition may be related to the heavy inflammatory response present in the lungs of
PbNK65-infected mice which leads to altered surfactant properties and increased lung
pathology.
Table 3. Total protein and phospholipid (PL) content in BAL fluid of PcAS or PbNK65 infected mice at different time points after the infection.
CTR PcAS day 8 PcAS day 10 PbNK65 day 8 PbNK65 day 10
Protein (μg/ml) 61.41 ± 16.3 97.57 ± 22.7 * 92.18 ± 13.0 * 635.52 ± 352.3 *; ° 1630.27 ± 142.1 **;°°
PL (μg/ml) 36.32 ± 3.4 91.76 ± 32.0* 80.12 ± 30.6* 77.63 ± 33.8* 162.3 ± 75.8**
Protein/PL 1.71 ± 0.5 1.06 ± 1.0 1.15 ± 0.6 8.18 ± 8.0 ** 10.05 ± 5.5 **
*p<0.05;
**p<0.0001 vs CTR;
° p<0.05;
°°p<0.001 vs PcAS n = 3–4, n = 5
doi:10.1371/journal.pone.0143195.t003
Fig 5. Protein content of the Large Aggregate (LA) fraction of BAL fluid from uninfected, PbNK65 or PcAS infectedmice. Bronchoalveolar lavage
(BAL) fluid samples were collected from control mice and mice infected with PbNK65 (n = 10 for day 8 post infection, n = 13 for day 10 post infection), or
PcAS (n = 8 for day 8 or 10 post infection). The large aggregate fraction (LA) was isolated and the content of proteins was determined. *p<0.05; **p<0.01;
***p<0.001 vs CTR; °°°p<0.001 vs PcAS for each time point.
doi:10.1371/journal.pone.0143195.g005
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Previously, we have shown that hemozoin contributes to pulmonary inflammation during
murine MA-ARDS [15]. In addition to its inflammatory effects, hemozoin also has a strong
pro-oxidant activity [43]. In this study, lung hemozoin levels were higher in PbNK65-infected
mice with pulmonary pathology compared to PcAS-infected mice with no signs of pulmonary
pathology. However, in spite of the relatively high hemozoin concentration and the increased
amounts of PUFAs present in the membranes of PbNK65-infected mice, no sign of increased
lipid peroxidation was detected in the lungs in the present study. The lung is an organ that—
due to its role in breathing—is very much exposed to oxygen and thus to oxidative insults.
Fig 6. Alterations in the lipid profile of the pulmonary surfactant of PbNK65 or PcAS infectedmice. (Panel A) Large aggregate (LA) and (Panel B)
small aggregate (SA) fractions of pulmonary surfactant were isolated from the BAL fluid of control mice and mice infected with PbNK65 or PcAS and the
percentage distribution of PL was determined. SM = Sphingomyelin, PE = phosphatidylethanolamine, PG = phosphatidylglycerol and
LPC = lysophosphatidylcholine. n = 5–7; * p< 0.05 vs CTR; ** p<0.001 vs CTR; ° p< 0.05, °° p< 0.01 vs PcAS for each time point.
doi:10.1371/journal.pone.0143195.g006
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Therefore, it has developed strong antioxidative defense mechanisms [44]. It is thus possible
that the oxidative stress and lipoperoxidation occuring in the lungs of mice with MA-ARDS,
do not exceed the antioxidant defenses of the lung tissue, thus significant oxidative damage is
not observed. Consistently with the absence of oxidative damage, pulmonary fibrosis was also
absent in the lungs of the studied mice. The latter may also be related to the acute nature of
MA-ARDS, as fibro-proliferation mainly develops during the subsequent, more chronic phase
of ARDS. Similar observations are reported from the post-mortem analysis of patients with
MA-ARDS, who usually do not demonstrate fibrosis unless they die after a long chronic period
of MA-ARDS [45, 46]
The surfactant is synthesized by type II pneumocytes in the epithelial lining of the alveoli
and secreted into the alveolar space. Increased surfactant levels may be due to an augmented
synthesis and/or impaired endocytosis of surfactant by type II cells, which might occur when
type II cell membranes are damaged or when plasma proteins are present in the alveolar space.
Pulmonary surfactant has a crucial role in the normal physiology of the lungs [47], and our
data suggest that the intrinsic activity of pulmonary surfactant may be significantly decreased
during murine MA-ALI/ARDS [47, 48]. In fact in the PbNK65-infected mice, vascular leakage
and pulmonary oedema result in increased protein levels, either in the total BAL supernatant
or in the BAL LA fraction. Plasma proteins are known to decrease the intrinsic surface activity
of surfactant [49]. Furthermore, an altered PL profile was detected in the LA fraction, which
was characterized by higher levels of SM and lower levels of PG. PG was also dramatically
decreased in the SA fraction to almost undetectable levels. PG is normally squeezed out of the
surfactant layer during compression and has been suggested to aid in the preferential enrich-
ment of DPPC in the surfactant film [39]. Similar changes in the PL composition have been
reported in other animal models of lung injury and in patients with established ARDS [25, 50]
and may be related to the altered surfactant reuptake, secretion, and/or synthesis by injured
alveolar cells or to PL contamination due to inflammatory cells. The increase of LPC in the SA
fraction is consistent with the action of secretory PLA2, whose activity has been detected in
BAL fluid of ARDS patients, in particular in the SA aggregates [51]. LPC is a known inhibitor
of surfactant activity and may further worsen lung functions [52].
Conclusion
Experimental MA-ARDS is associated with severe inflammation, oedema and, as shown here,
modifications of the lipid profile of both lung tissue and pulmonary surfactant. Total PLs, and
PC in particular, together with ChoE levels were significantly increased in lung tissue. The fatty
acid distribution was also altered during lung pathology, with increased palmitic acid and
decreased stearic and oleic acid levels. With regard to the alveolar surfactant, a significant
increase in the protein content was found, probably due to vascular leakage. Alterations in the
PL composition, with increased levels of LPC and SM, and decreased levels of PG were also
observed. Since LPC is a known inhibitor of surfactant activity, these changes together with the
intense inflammation, may contribute to the impairment of lung functions and to the severity
of murine MA-ALI/ARDS.
Supporting Information
S1 Fig. Oxidative damage and fibrosis in lung tissue of PbNK65 or PcAS infected mice.
MDA content (A) (pmole/mg protein) and OH-proline content (μg/mg protein) (B) in infected
and non infected mice at day 8 or 10 days post infection. n = 7–8.
(TIF)
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S2 Fig. Amount of the LA fraction of PbNK65 or PcAS infected mice. Percentage of LA frac-
tion obtained from uninfected or PbNK65- or PcAS-infected mice at 8 or 10 days post infec-
tion.
(TIF)
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